Matthew Gately has been certified by the Supreme Court of New Jersey as a Civil Trial Attorney and has tried cases in state and federal courts, as well as in private arbitration. He primarily handles complex commercial/contractual disputes and class/collective actions. Matt has been part of the litigation team representing direct purchasers of pharmaceutical products in several antitrust and RICO class actions, including In re K-Dur Antitrust Litigation (D.N.J.) ($60.2m settlement), In re Lipitor Antitrust Litigation (D.N.J.) ($93m settlement), and In re Effexor XR Antitrust Litigation (D.N.J.) ($39m settlement against one defendant). He currently serves as interim liaison counsel for the Class Action Track in In re Insulin Pricing Litigation (D.N.J.), and for the Direct Purchaser Plaintiffs in In re Effexor XR Antitrust Litigation and In re Vascepa Antitrust Litigation (D.N.J.). He has also served as counsel in securities class actions and derivative litigations that have resulted in significant recoveries, including Shumacher v. Osmotica Pharma (N.J. Superior Court) ($5.25m settlement) and In re Prudential Financial Securities Litigation (D.N.J.) ($35m settlement).
Additionally, Matt has represented clients in personal injury and malpractice cases, investor litigation/arbitration, partnership and other intra-business disputes, and employment discrimination matters. He has also provided counsel to New Jersey state agencies in environmental cost-recovery litigations.
Matt is AV rated by Martindale-Hubbell, was named by the New Jersey Law Journal as one of the “New Leaders of the Bar,” and has been listed as a “Rising Star” by Super Lawyers since 2017. He currently serves as a Trustee of the Association of the Federal Bar of New Jersey and the Co-Chair of the Bergen County Bar Association’s Federal Practice Committee.
Prior to joining Cohn Lifland, Matt was senior law clerk to the Hon. Madeline Cox Arleo, U.S.D.J., D.N.J., law clerk to the Hon. Michael A. Hammer, U.S.M.J., D.N.J., and worked for several years in the commercial litigation group of an AmLaw 100 law firm.
Matt graduated from Columbia Law School, where he was a Harlan Fiske Stone Scholar and member of the Columbia Business Law Review. His student note addressing proposed hedge fund regulation was published in the 2008 volume of that journal. He received his B.A. (in three years), magna cum laude, from Lafayette College with a double major in Government & Law and Philosophy.
*No aspect of this advertisement has been approved by the Supreme Court of New Jersey. A description of the selection methodology can be found here.
